Internal Code: MAS1679
Although global morbidity and mortality have decreased substantially, malaria, a parasite infection of red blood cells, still kills roughly 2000 people per day, most of whom are children in Africa. Two factors largely account for these decreases; increased deployment of insecticide-treated bednets and increased availability of highly effective
artemisinin combination treatments. In large trials, parenteral artesunate (an artemisinin derivative) reduced severe
malaria mortality by 22·5% in Africa and 34·7% in Asia compared with quinine, whereas adjunctive interventions
have been uniformly unsuccessful. Rapid tests have been an important addition to microscopy for malaria diagnosis.
Chemopreventive strategies have been increasingly deployed in Africa, notably intermittent sulfadoxine–
pyrimethamine treatment in pregnancy, and monthly amodiaquine–sulfadoxine–pyrimethamine during the rainy season months in children aged between 3 months and 5 years across the sub-Sahel. Enthusiasm for malaria elimination has resurfaced. This ambitious but laudable goal faces many challenges, including the worldwide economic downturn, diffi culties in elimination of vivax malaria, development of pyrethroid resistance in some anopheline mosquitoes, and the emergence of artemisinin resistance in Plasmodium falciparum in southeast Asia.We review the epidemiology, clinical features, pathology, prevention, and treatment of malaria.
Question 1. What type of disease is malaria and how does it physiologically damage the human body?
Question 2. Discuss the symptoms and duration of malaria and the way it is transmitted and spread between people.
Question 3. Describe the mortality and morbidity of malaria in people of different ages with relevance to the prevalence of this health issue worldwide.
Question 4. Discuss worldwide strategies of malaria diagnosis, prevention and treatment and why these strategies may differ between regions or countries.
Enjoy 40% Discount on All Assignments. Call: +61 282 942 025